UK pharma major GSK (LSE: GSK) and US biotech SpringWorks Therapeutics are to end their collaboration combining Blenrep (belantamab mafodotin) and Ogsiveo (niro 11 June 2024
British pharma major AstraZeneca's (LSE: AZN) bid to broaden the label for Tagrisso (osimertinib) will be considered under the Priority Review scheme. 10 June 2024
Swiss pharma giant Roche (ROG: SIX) has announced that the European Commission (EC) has approved Alecensa (alectinib) monotherapy, as adjuvant treatment followi 10 June 2024
Chicagoan biopharma giant AbbVie has announced encouraging topline results from its Phase II PICCOLO trial of Elahere (mirvetuximab soravtansine). 7 June 2024
Treos Bio, a biotech using data science and proprietary biomarkers to develop precision peptide immunotherapies, has presented results from its Phase II OBERTO- 4 June 2024
The market for branded multiple myeloma drugs is projected to grow to $33 billion by 2030, up from $23.5 billion in 2023, according to Bloomberg Intelligence (B 4 June 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.